Should You Buy Charles River Laboratories International, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Charles River Laboratories International, Inc. (CRL) carries a solid Quality of Company rating of 6.9/10. Trading at $272.88, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.
The short answer: 1 of 8 CirclFi valuation models project upside for Charles River Laboratories International, Inc. (CRL) at $272.88 — the model consensus leans bearish, with a Quality Score of 6.9/10 and Value-Trap risk of 43/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Charles River Laboratories International, Inc. (CRL) in 2026?
What Is the Bull Case vs the Bear Case for Charles River Laboratories International, Inc. (CRL)?
| Bull case — $386.48 target (+41.6%) | Bear case — $29.29 target (-89.3%) |
|---|---|
| According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model targets a fair value of $386.48 (+41.6%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Value Trap algorithm, the stock shows moderate caution signals, meaning investors should verify that apparent undervaluation isn't masking declining business quality. |
| Industry tailwind: therapeutic area leadership could provide meaningful support for Charles River Laboratories International, Inc.'s revenue and margin trajectory in the Diagnostics & Research space. | According to the CirclFi Deep Alpha Valuation Engine, the Earnings Power Value (EPV) model sees the stock as overvalued with a fair value of $29.29 (-89.3%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +130.9% spread between the most bullish and bearish models, signaling elevated analytical uncertainty. | |
| Industry headwind: drug pricing legislation represents a meaningful risk for Charles River Laboratories International, Inc. and its Diagnostics & Research peers. |
How Does CRL Compare to Its Diagnostics & Research Peers?
Valuation data pages: FLGT · PRPO · GH · XGN · ADPT · RDNT · IMDX · ICLR · DGX · IDXX · MEDP
Which Other Stocks Score Like CRL on Quality?
Closest companies to CRL’s Quality of Company score of 6.9/10, across all industries.
- CEPL — Capstone Energy+, Inc. (QOC 6.9) · analysis
- CYRX — Cryoport, Inc. (QOC 6.9) · analysis
- CGAU — Centerra Gold Inc. (QOC 6.9) · analysis
- DD — DuPont de Nemours, Inc. (QOC 6.9) · analysis
- HBNC — Horizon Bancorp, Inc. (QOC 6.9) · analysis
- BKH — Black Hills Corporation (QOC 6.9) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
So Is Charles River Laboratories International, Inc. (CRL) Worth Buying in 2026?
Our valuation engine sends a clear cautionary signal on Charles River Laboratories International, Inc. at $272.88. 7/8 models flag overvaluation, median fair value sits at $101.68 (-62.7%), and the risk-reward profile appears unfavorable. Quality at 6.9/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. Charles River Laboratories International, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About CRL Stock?
Should I buy CRL stock right now?
Based on CirclFi's multi-model analysis, 1 of 8 models see upside for CRL at $272.88. The models are divided, which means the investment case depends heavily on your assumptions about Charles River Laboratories International, Inc.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Charles River Laboratories International, Inc.?
Key risks include: an elevated Value Trap score of 43/100, suggesting apparent undervaluation may mask deteriorating fundamentals; wide model disagreement (1219% spread), signaling high uncertainty; general market and sector-specific risks affecting Diagnostics & Research companies. Always diversify and consult a financial advisor.
How does CRL compare to its competitors?
Among Diagnostics & Research peers, CRL holds a Quality Score of 6.9/10. Comparable companies include FLGT (QOC 7.0), PRPO (QOC 6.7), GH (QOC 7.0). The relative ranking helps investors identify whether CRL offers better fundamental quality than alternatives in the same sector.
Is CRL a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. CRL's Quality Score of 6.9/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy CRL at?
CirclFi does not provide target buy prices or price alerts. However, our 8 active models produce fair value estimates ranging from $29.29 to $386.48. At $272.88, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for CRL.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad